Biology subjects

An, H. H.

Publications and source records attributed to An, H. H..

5 recordsLinked to original sources

bioRxiv2026

An Intronic SINE at Pou5f1 Links Hormone Signaling to Blastocyst Hatching

Before implantation, mammalian embryos must escape from the zona pellucida, a protective glycoprotein coat that surrounds the blastocyst. This process, known as hatching, is essential for uterine attachment and has been viewed largely as a mechanical consequence of blastocyst expansion and zona weakening. Whether hatching is actively timed by embryo-intrinsic gene regulation remains unclear. Here we show that timely hatching of mouse embryos requires signal-responsive repression of Pou5f1/OCT4 in the trophectoderm by a single intronic B2 short interspersed nuclear element. Deleting this element preserves blastocyst formation and stem-cell competence, but disrupts trophectodermal OCT4 repression, delays zona escape, causes hatching-uterine receptivity mismatch, perturbs implantation-site organization and reduces peri-implantation fitness. CRISPR activation screening, siRNA and pharmacological perturbation, and defined progesterone/estradiol/EGF culture conditions identify an ESRRA-linked endocrine/growth-factor response that requires the B2 element to consolidate trophectoderm maturation. Comparative analyses further show that young intronic SINEs are enriched in developmental gene programs, whereas human POU5F1 intronic Alu elements exhibit genetic constraint and repressive potential. These findings identify intronic SINEs as molecular entry points that couple extracellular cues to lineage-restricted transcriptional control and morphogenic transition.

developmental biology↗

bioRxiv2025

Restraint of TGFβ family signaling by SMAD7 is necessary for hematopoietic stem cell maturation in the embryo.

Hematopoietic stem cells (HSCs), defined as cells that can engraft an adult when transplanted, mature from precursors (pre-HSCs) that differentiate from hemogenic endothelial cells (HECs) in the embryo. Many signaling pathways required to generate the first hematopoietic stem and progenitor cells in the embryo are well-characterized, but how HSCs mature from pre-HSCs is poorly understood. Here we show that "mothers against decapentaplegic homolog 7" (SMAD7), a negative regulator of transforming growth factor beta (TGF{beta}) and bone morphogenetic protein (BMP) signaling, is required for pre-HSC to HSC maturation. Deletion of Smad7 in endothelial cells allows the formation of pre-HSCs from HECs but impairs their maturation into HSCs. The data indicate that although TGF{beta} and BMP signaling are required for the generation of HECs and for HECs to undergo an endothelial-to-hematopoietic transition to generate pre-HSCs, one or both pathways must be subsequently down-regulated for effective pre-HSC to HSC maturation.

developmental biology↗

bioRxiv2024

Human erythroid progenitors express antigen presentation machinery

Early-life immune exposures can profoundly impact lifelong health. However, functional mechanisms underlying fetal immune development remain incomplete. Erythrocytes are not typically considered active immune mediators, primarily because erythroid precursors discard their organelles as they mature, thus losing the ability to alter gene expression in response to stimuli. Erythroid progenitors and precursors circulate in human fetuses and neonates. Although there is limited evidence that erythroid precursors are immunomodulatory, our understanding of the underlying mechanisms remains inadequate. To define the immunobiological role of fetal and perinatal erythroid progenitors and precursors, we analyzed single cell RNA-sequencing data and found that transcriptomics support erythroid progenitors as putative immune mediators. Unexpectedly, we discovered that human erythroid progenitors constitutively express Major Histocompatibility Complex (MHC) class II antigen processing and presentation machinery, which are hallmarks of specialized antigen presenting immune cells. Furthermore, we demonstrate that erythroid progenitors internalize and cleave foreign proteins into peptide antigens. Unlike conventional antigen presenting cells, erythroid progenitors express atypical costimulatory molecules and immunoregulatory cytokines that direct the development of regulatory T cells, which are critical for establishing maternal-fetal tolerance. Expression of MHC II in definitive erythroid progenitors begins during the second trimester, coinciding with the appearance of mature T cells in the fetus, and is absent in primitive progenitors. Lastly, we demonstrate physical and molecular interaction potential of erythroid progenitors and T cells in the fetal liver. Our findings shed light on a unique orchestrator of fetal immunity and provide insight into the mechanisms by which erythroid cells contribute to host defense.

immunology↗

bioRxiv2024

Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease

Efforts to cure BCR::ABL1 B cell acute lymphoblastic leukemia (Ph+ ALL) solely through inhibition of ABL1 kinase activity have thus far been insufficient despite the availability of tyrosine kinase inhibitors (TKIs) with broad activity against resistance mutants. The mechanisms that drive persistence within minimal residual disease (MRD) remain poorly understood and therefore untargeted. Utilizing 13 patient-derived xenograft (PDX) models and clinical trial specimens of Ph+ ALL, we examined how genetic and transcriptional features co-evolve to drive progression during prolonged TKI response. Our work reveals a landscape of cooperative mutational and transcriptional escape mechanisms that differ from those causing resistance to first generation TKIs. By analyzing MRD during remission, we show that the same resistance mutation can either increase or decrease cellular fitness depending on transcriptional state. We further demonstrate that directly targeting transcriptional state-associated vulnerabilities at MRD can overcome BCR::ABL1 independence, suggesting a new paradigm for rationally eradicating MRD prior to relapse. Finally, we illustrate how cell mass measurements of leukemia cells can be used to rapidly monitor dominant transcriptional features of Ph+ ALL to help rationally guide therapeutic selection from low-input samples. HIGHLIGHTSO_LIRelapse after remission on TKI can harbor mutations in ABL1, RAS, or neither C_LIO_LIMutations and development-like cell state dictate fitness in residual disease C_LIO_LICo-targeting cell state and ABL1 markedly reduces MRD C_LIO_LIBiophysical measurements provide an integrative, rapid measurement of cell state C_LI

cancer biology↗

bioRxiv2024

BMI1 regulates human erythroid self-renewal through both gene repression and gene activation

The limited proliferative capacity of erythroid precursors is a major obstacle to generate sufficient numbers of in vitro-derived red blood cells (RBC) for clinical purposes. We and others have determined that BMI1, a member of the polycomb repressive complex 1 (PRC1), is both necessary and sufficient to drive extensive proliferation of self-renewing erythroblasts (SREs). However, the mechanisms of BMI1 action remain poorly understood. BMI1 overexpression led to 10 billion-fold increase BMI1-induced (i)SRE self-renewal. Despite prolonged culture and BMI1 overexpression, human iSREs can terminally mature and agglutinate with typing reagent monoclonal antibodies against conventional RBC antigens. BMI1 and RING1B occupancy, along with repressive histone marks, were identified at known BMI1 target genes, including the INK-ARF locus, consistent with an altered cell cycle following BMI1 inhibition. We also identified upregulated BMI1 target genes with low repressive histone modifications, including key regulator of cholesterol homeostasis. Functional studies suggest that both cholesterol import and synthesis are essential for BMI1-associated self-renewal. These findings support the hypothesis that BMI1 regulates erythroid self-renewal not only through gene repression but also through gene activation and offer a strategy to expand the pool of immature erythroid precursors for eventual clinical uses.

cell biology↗